Published medical commentary describes GLP-1 microdosing as administering fractional doses smaller than standard protocols and titrating them to an individual patient’s tolerance and response.
It does not mean taking a minimal dose for vague wellness benefits or calculating a dose from social media. Microdosing is off-label, is not established in clinical guidelines, and has not been tested as a standalone protocol in randomized controlled trials.
Rivas uses compounded medication from multi-dose vials in appropriate cases. This can permit precise provider-directed increments, but compounded medications are not FDA-approved finished products and are not the same as brand-name Wegovy or Zepbound.